Clinical Trials Browser

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03923270 2026-01-08

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Phase 1 Active not recruiting

25 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06077500 2026-01-06

DAREONᵀᴹ-8

Phase 1 Active not recruiting

45 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT06211036 2025-12-17

DeLLphi-305

Phase 3 Active not recruiting

563 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT03703297 2025-11-21

ADRIATIC

Phase 3 Active not recruiting

730 enrolled 19 charts 1 FDA

Thoracic

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT04397003 2025-10-22

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

Phase 2 Active not recruiting

6 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT03043872 2025-10-21

CASPIAN

Phase 3 Active not recruiting

987 enrolled 42 charts 2 FDA

Thoracic

Small Cell Lung Carcinoma

NCT04472949 2025-10-01

Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

Phase 2 Active not recruiting

46 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05796089 2025-08-26

CHEST RT

Phase 2 Active not recruiting

35 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT05617963 2025-06-15

DURVALUNG

Phase 2 Recruiting

100 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04774380 2025-05-23

LUMINANCE

Phase 3 Completed

152 enrolled 17 charts

Thoracic

Small Cell Lung Carcinoma

NCT06419179 2025-05-20

GUIDANCE

Phase 2 Enrolling by invitation

29 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT03509012 2025-01-14

CLOVER

Phase 1 Completed

105 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT06719336 2024-12-05

Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)

Phase 3 Not yet recruiting

182 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04951115 2024-11-26

A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer

Phase 2 Terminated

6 enrolled 13 charts

Thoracic

Small Cell Lung Carcinoma

NCT04504669 2024-11-05

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Phase 1 Completed

60 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05572476 2024-06-05

LURBIMUNE

Phase 2 Withdrawn

Thoracic

Small Cell Lung Carcinoma

NCT06223711 2024-04-05

Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC

Phase 2 Recruiting

43 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04610684 2024-03-13

Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases

Phase 2 Terminated

3 enrolled 13 charts

CNSThoracic

Brain Neoplasms, Small Cell Lung Carcinoma

NCT05092412 2024-01-12

Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC

Phase 2 Unknown

30 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04985851 2023-12-01

To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.

Phase NA Unknown

90 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT03963414 2023-08-28

A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

Phase 1 Terminated

1 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

441 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT05484583 2022-08-05

Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases

Phase 2 Not yet recruiting

58 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05245994 2022-02-18

An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese

Phase 2 Unknown

60 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT02701400 2021-06-22

Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer

Phase 2 Completed

18 enrolled 13 charts

Thoracic

Small Cell Lung Carcinoma

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

40 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04314297 2020-03-19

Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

Phase 2 Unknown

33 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT03585998 2020-03-02

Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer

Phase 2 Unknown

51 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT03085849 2018-12-10

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

Phase 1 Completed

2 enrolled

Thoracic

Small Cell Lung Carcinoma

Clinical Trials

MK-6070-002

IMFINZI-subQ

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

ALBORAN

DeLLphi-312

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

(DeLLphi-310)

SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer

MEDIOLA

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

DAREONᵀᴹ-8

DeLLphi-305

ADRIATIC

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

CASPIAN

Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

CHEST RT

DURVALUNG

LUMINANCE

GUIDANCE

CLOVER

Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)

A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

LURBIMUNE

Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC

Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases

Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC

To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.

A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases

An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese

Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer

SGI-110 Plus Durvalumab/Tremelimumab in SCLC